THE PRECIPICE OF PRECISION MEDICINE

There’sno doubt that we’re currently living in the true age of digitization—one that’s been accelerated over recent years via technological breakthroughs and adoption. And, given constant advancements within biomedicine, it’s no surprise that its convergence with the latest technologies is leading to mind-boggling discoveries and innovative solutions to help address challenges. As a result, research and study concerning precision medicine and the development of more personalized therapies and treatments has never been more intense, yielding some of the most incredible possibilities and unleashing boundless potential.

Without proper investment into the biomanufacturing and life sciences sectors, however, much of the possibilities and potential posed by precision medicine could go untapped. Within the Spring issue of BioLab Business magazine, we highlight the Government of Canada’s recently announced pledge to establish a network of new research hubs in order to strengthen the sectors and related research.

In an effort to uncover some of the incredible work that’s being conducted by scientists and technicians in laboratories across the country, we highlight the studies of Cam Meaney, a PhD candidate at the University of Waterloo, and the ways in which precision mapping of tumour growth may pave the way toward more accurately projecting future accelerations, leading to much more personalized and improved treatment and care.

www.BioLabmag.com

One year subscription: Canada $35, US $35 and foreign $95. Single copies $9. Please add GST/HST where applicable. BioLab Business subscription and circulation enquiries: Garth Atkinson, biondj16@publicationpartners.com (Fax: 905.509.0735).

Subscriptions to business address only. On occasion, our list is made available to organizations whose products or services may be of interest to you. If you’d rather not receive information, write to us at the address above or call 905.509.3511.

The contents of this publication may not be reproduced either in part or in whole without the written consent of the publisher. GST Registration #R124380270.

PUBLICATIONS MAIL AGREEMENT NO. 40063567

RETURN UNDELIVERABLE CANADIAN ADDRESSES TO CIRCULATION DEPT.

205 RIVIERA DRIVE, UNIT 1 MARKHAM, ON L3R 5J6 email: biond@publicationpartners.com

We also feature the findings of a decade-long study conducted by 44 researchers representing 23 different institutions across Europe and Canada which reveals a link between genetic changes that occur in kidney cancer patients and the likelihood of the cancer recurring. Leveraging DNA sequencing techniques, it’s leading to a better understanding of the disease and the ways in which individual patients should be assessed and treated.

And, we explore the work being done at Vita Therapeutics—a cell engineering company that’s harnessing the power of genetics inside its neuro muscular platform to improve outcomes for muscular dystrophy patients, presenting incredible promise for future therapies to treat a range of degenerative muscle conditions.

As technology and medical research continues to advance at incomprehensible speeds, their confluence is sparking an exciting new age of life sciences. And, supported by biomanufacturing breakthroughs, it’s leading to a new way of approaching patient treatment and care.

Chris Forbes PUBLISHER & CEO

Printed

Canada

BY DAVID SUZUKI WITH CONTRIBUTIONS FROM QUEBEC AND ATLANTIC CANADA DIRECTOR SABAA KHAN